Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Instagram Outage Disrupts Thousands of U.S. Users 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
SAN DIEGO, Feb. 02, 2018 -- After Tuesday’s State of the Union Address, The Recover examines Trump’s message to lower prescription costs and fight for the dying rights of those with terminal conditions.
|
|||||
In his speech he addressed the “Right to Try” Legislation that was proposed but is waiting on approval from the FDA. "We also believe that patients with terminal conditions should have access to experimental treatments that could potentially save their lives," the president said.
"People who are terminally ill should not have to go from country to country to seek a cure — I want to give them a chance right here at home. It is time for the Congress to give these wonderful Americans the 'right to try,'" he says.
The prescription drug cost has been rising in recent years, with medications dramatically increasing 44% since 2003, and continues to grow with out interference. Trump proposes to prevent that from happening under his administration, but without a clear plan.
"One of my greatest priorities is to reduce the price of prescription drugs. In many other countries, these drugs cost far less than what we pay in the United States," Trump stated.
"And it is very, very unfair," he said. "That is why I have directed my administration to make fixing the injustice of high drug prices one of our top priorities. Prices will come down."
The President will also have to address the issue that some of these prescription drugs have led to the opioid problem the country faces. Other pain relievers and stimulant prescription drugs can be misused and can cause an addiction to the user.
Alex Azar was in attendance at the address, a former drug company executive, lobbyist and spokesperson who has been sworn in as Secretary of Health and Human Services under President Trump's cabinet. Mr. Azar’s former profession brings into question how someone from that industry could possibly have a hand in disrupting their profit and helping the people of America. While introducing Azar, Trump mentioned several times that he shared his desire in reducing prescription drug prices.
Author: Kevin Leonard
Organization: TheRecover.com
Address: 27420 Jefferson Ave 101a, Temecula, CA 92590
Phone: 888-510-3898
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/cf3a285e-8af4-4ac2-89ce-40e8b07cda15
